Cramer: 27% Biotech Rally Leads Stocks Working Beyond Tech
SkimNews Take
The breadth Cramer highlights may not be independent leadership but a second-order effect of the same risk-on/risk-off pulse driving tech, since biotech, transports, and deal activity all historically move with risk appetite — meaning the market's underlying volatility regime hasn't actually broadened.
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Wells Fargo CEO Charlie Scharf has cut roughly 23% of the workforce and is recruiting senior JPMorgan talent to build out M&A and underwriting, with Cramer predicting analysts who disliked the quarter will be 'proven wrong' within two years as the stock has a P/E of just 12.
- J.B. Hunt reported a 'terrific upside surprise' this week as the trucking and logistics recession played out, with weaker players exiting and pricing firming; Cramer also added to FedEx Freight (spun off June 1) earlier this month.
- The SPDR S&P Biotech ETF is up more than 27% year-to-date amid a 'very large wave of biotech acquisitions' that Cramer notes do not all involve Eli Lilly.
- Stripe has made an offer to acquire PayPal, a move Cramer called 'seminal' and 'totally overlooked' that could consolidate a crowded fintech space alongside Fiserv, Global Payments, Toast, Fair Isaac, Block, and Affirm.
- SpaceX's post-IPO decline is 'orderly,' and Cramer says underwriters appear to be letting short sellers pair shorts with shares that will be unlocked over time, preventing broader contagion across space, energy, and self-driving names.
- The memory and data-center trade is unwinding at a 'furious pace' across SK Hynix, Seagate, Western Digital, Sandisk, Micron, Arm, AMD, and Intel, with Cramer calling Intel 'a terrific buy' even after adding to his position twice last week amid forced hedge-fund selling.
- Retail, rails, and airlines — specifically Target, Union Pacific, Delta, and United — are delivering strong percentage gains when paired with even a 'half-decent' earnings story, reinforcing Cramer's view that the market is exerting discipline on tech rather than breaking down.
Why it matters: Cramer is reframing the selloff as targeted market discipline, not systemic weakness: the SPDR Biotech ETF is up 27% YTD, Wells Fargo is restructuring toward higher-margin M&A revenue, and the memory unwind is driven by forced hedge-fund selling rather than deteriorating fundamentals. If non-tech sectors keep delivering easy wins while tech stays punished, investors overweight in tech face the first real risk of prolonged relative underperformance, with capital rotation accelerating the divergence.
